Xeljanz and Intestinal polyp - a phase IV clinical study of FDA data

Summary:

Intestinal polyp is reported as a side effect among people who take Xeljanz (tofacitinib citrate), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Enbrel, and have Psoriatic arthropathy.

The phase IV clinical study analyzes which people have Intestinal polyp when taking Xeljanz. It is created by eHealthMe based on reports of 238,928 people who have side effects when taking Xeljanz from the FDA, and is updated regularly.

What is Xeljanz?

Xeljanz has active ingredients of tofacitinib citrate. It is often used in rheumatoid arthritis. eHealthMe is studying from 239,081 Xeljanz users. Check the latest studies of Xeljanz.

What is Intestinal polyp?

Intestinal polyp (small growths in the bowel with the potential for further growth) is found to be associated with 289 drugs and 420 conditions by eHealthMe. Check the latest studies of Intestinal polyp.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

238,928 people reported to have side effects when taking Xeljanz.
Among them, 99 people (0.04%) have Intestinal polyp.

Among these 99 people:

How long have people been on Xeljanz when they have Intestinal polyp? *

What is the gender of people who have Intestinal polyp when taking Xeljanz? *

female: 47.96 %
male: 52.04 %

What is the age of people who have Intestinal polyp when taking Xeljanz? *

What are other drugs people take besides Xeljanz? *

What are other side effects people have besides Intestinal polyp? *

Drug Ineffective: 88 people, 88.89%
Memory Loss: 84 people, 84.85%
Synovitis (inflammation of the synovial membrane): 84 people, 84.85%
Kidney Stones: 84 people, 84.85%
Leukopenia (less number of white blood cells in blood): 84 people, 84.85%
Mobility Decreased (ability to move is reduced): 84 people, 84.85%
Drug Intolerance (drug sensitivity): 84 people, 84.85%
Bone Erosion: 84 people, 84.85%
C-Reactive Protein Abnormal: 83 people, 83.84%
Colitis (inflammation of colon): 62 people, 62.63%

What are the existing conditions these people have? *

Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 20 people, 20.20%
Pneumonia: 11 people, 11.11%
Limb Discomfort (discomfort in leg): 11 people, 11.11%
Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 5 people, 5.05%

* Approximation only. Some reports may have incomplete information.

Do you take Xeljanz and have Intestinal polyp?

- Check whether Intestinal polyp is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Xeljanz:

Xeljanz (239,081 reports)

Browse all side effects of Xeljanz:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Intestinal polyp:

Intestinal polyp (289 drugs)

Browse all the conditions that are associated with Intestinal polyp:

Intestinal polyp (420 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on tofacitinib citrate (the active ingredients of Xeljanz) and Xeljanz (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.